

Increasingly successful attendance in major ortho EU & US conferences and North America launch of BIOCERA-VET COMBO-CLEAN

- ▼ Commercial success at the ESVOT congress and ACVS conference with an ever-growing number of vets visiting TheraVet's booths
- ▼ BIOCERA-VET use for surgical management of canine osteosarcoma highlighted in a poster session
- ▼ Launch of BIOCERA-VET COMBO-CLEAN, a unique antibiotic long-lasting releasing bone substitute, in North America

Gosselies (Wallonia, Belgium), October 18, 2023 – 7.30 am CEST – TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, continues **its efforts on the deployment of its commercial strategy in attending major conferences dedicated to veterinary surgeons in Europe and United-States.**

The Company attended the annual congress of the European Society of Veterinary Orthopaedics and Traumatology (ESVOT) (5-7 October, Venice, Italy) organized under a new format to address a specific topic in-depth and gathered nearly 350 participants. This year focus on “Complication in Traumatology” was addressing **topics of interest to BIOCERA-VET such as the full session dedicated to the management of bone infection where the use of local antibiotherapy was debated.** Furthermore, BIOCERA-VET was also **highlighted in a poster dedicated to osteosarcoma management:** *“In situ minimally invasive calcium phosphate cement injection for conservative surgical management of appendicular osteosarcoma in typical and atypical locations in dogs”*. Finally, the Company strong commercial presence allowed to meet with ~20% of the participants.

After Europe, then Company participated to the ACVS surgery Summit, organized from October 12 to 14 (Louisville, USA) by the prestigious American College of Veterinary Surgery. The ACVS represent the largest event dedicated to veterinary surgery in USA with more than 1500 participants (from USA and abroad) and about 150 exhibitors with all the important players in orthopaedic surgery represented. The Company strong commercial presence allowed to meet with ~10% of the participants.

After Europe in May 2023, the Company takes advantage of this important event to **officially launch BIOCERA-VET® Combo-Clean**, the new reference of BIOCERA-VET® product line, **in North America** (USA and Canada). BIOCERA-VET® Combo-Clean is available on a dedicated website (www.bioceravet.com). **BIOCERA-VET® Combo-Clean is the first-of-its-kind sustained**



antibiotic releasing bone substitute allowing the local of management bone infection while supporting bone healing and mechanical strength. Proof of the interest shown in this new reference, the first sales were recorded during the ACVS conference.

About TheraVet SA

TheraVet is a veterinary biotechnology company specializing in osteoarticular treatments for companion animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from joint and bone diseases. For pet owners, the health of their pets is a major concern and TheraVet's mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris and Brussels, has its head office in Belgium (Gosselies) with a US subsidiary.

For more information, visit the TheraVet [website](#) or follow us on [LinkedIn](#) / [Facebook](#) / [Twitter](#)

About BIOCERA-VET

In close collaboration with an international scientific board, THERAVET® has developed a new line of calcium-phosphate and biological bone substitutes, BIOCERA-VET®. BIOCERA-VET® is a full range of innovative, easy-to-use, efficient & cost-effective bone substitutes indicated in bone surgeries where a bone graft is required and as a palliative alternative in the management of canine osteosarcoma. Based on extremely promising clinical results, this line offers the possibility of a better, more convenient and more efficient orthopedic surgery.

BIOCERA-VET® is declined in different lines:

- BIOCERA-VET® BONE SURGERY RTU, a ready-to-use highly injectable self-hardening calcium-phosphate cement
- BIOCERA-VET® SMARTGRAFT, a naturally osteoconductive bone graft
- BIOCERA-VET® GRANULES, an affordable biocompatible calcium-phosphate bone substitute
- BIOCERA-VET® OSTEOSARCOMA RTU, a ready-to-use highly injectable calcium-phosphate bone substitute for cementoplasty
- BIOCERA-VET® COMBO-CLEAN, a local and long-lasting antibiotic delivery calcium-phosphate bone substitute

For more information, visit [BIOCERA-VET](#) website.

Contacts

TheraVet

Chief Operating Officer

Sabrina Ena

investors@thera.vet

Tel: +32 (0) 71 96 00 43

NewCap

Investor Relations and

Financial Communications

Théo Martin / Nicolas Fossiez

theravet@newcap.eu

Tel: +33 (0)1 44 71 94 94

NewCap Belgique

Press Relations

Laure-Eve Monfort

lemonfort@thera.vet

Tel: + 32 (0) 489 57 76 52

Press Relations

Arthur Rouillé

theravet@newcap.eu

Tel: +33 (0)1 44 71 00 15